Equillium Inc. (EQ)
0.82
0.05 (6.08%)
At close: Mar 24, 2025, 3:55 PM
0.81
-1.01%
After-hours: Mar 24, 2025, 07:55 PM EDT
6.08% (1D)
| Bid | 0.79 |
| Market Cap | 28.92M |
| Revenue (ttm) | 45.92M |
| Net Income (ttm) | -4.62M |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -6.8 |
| Forward PE | -0.63 |
| Analyst | Hold |
| Ask | 0.83 |
| Volume | 64,897 |
| Avg. Volume (20D) | 831,786 |
| Open | 0.76 |
| Previous Close | 0.77 |
| Day's Range | 0.76 - 0.82 |
| 52-Week Range | 0.49 - 2.90 |
| Beta | 1.87 |
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 12, 2018
Employees 45
Stock Exchange NASDAQ
Ticker Symbol EQ
Website https://equilliumbio.com
Analyst Forecast
According to 2 analyst ratings, the average rating for EQ stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 512.59% from the latest price.
Stock Forecasts1 month ago
+33.03%
Equillium shares are trading higher after the comp...
Unlock content with
Pro Subscription
4 months ago
-12.33%
Equillium shares are trading lower after the company reported worse-than-expected Q3 sales results.
